title: Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study.
abstract: OBJECTIVE
  A phase II study was conducted to determine the efficacy of oxaliplatin therapy in patients with platinum-resistant or refractory epithelial ovarian carcinoma.
  
  
  METHODS
  Eligible patients were to receive oxaliplatin 130 mg/m2 intravenously over 2 hours, every 21 days, until progression of disease or adverse effects prohibited further therapy.
  
  
  RESULTS
  Of 25 patients entered onto the study, 23 were eligible and assessable. There were no patients with complete response. One patient (4.3%) achieved a partial response, with a response duration of 6.4 months. Nine patients (39.1%) experienced stable disease, with a median duration of 5.6+ months (range, 1.8 to 13.1 months). The most frequently reported drug-related toxicities were hematologic, gastrointestinal, and neurologic.
  
  
  CONCLUSIONS
  Oxaliplatin as a single agent has minimal activity in patients with platinum-resistant or refractory ovarian cancer at the dosage and schedule tested. However, future studies of oxaliplatin combined with other active agents in women with platinum-naïve or platinum-sensitive epithelial ovarian carcinoma may be indicated.
authors.affiliation: Washington University School of Medicine, St Louis, MO 63130, USA. fracasso@im.wustl.edu.
authors.forename: Paula M
authors.initials: PM
authors.lastname: Fracasso
authors.forename: John A
authors.initials: JA
authors.lastname: Blessing
authors.forename: Mark A
authors.initials: MA
authors.lastname: Morgan
authors.forename: Anil K
authors.initials: AK
authors.lastname: Sood
authors.forename: James S
authors.initials: JS
authors.lastname: Hoffman
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000077150:Oxaliplatin; D017671:Platinum Compounds / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D017671:Platinum Compounds; D000077150:Oxaliplatin